{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T05:03:34Z","timestamp":1694927014060},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,5,5]],"date-time":"2011-05-05T00:00:00Z","timestamp":1304553600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s12032-011-9961-5","type":"journal-article","created":{"date-parts":[[2011,5,4]],"date-time":"2011-05-04T13:03:25Z","timestamp":1304514205000},"page":"1391-1396","source":"Crossref","is-referenced-by-count":9,"title":["First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report"],"prefix":"10.1007","volume":"29","author":[{"given":"Klaus","family":"Pietzner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Schoberth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fclten","family":"Oskay-\u00d6zcelik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Kuhberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horst","family":"Lindhofer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jalid","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,5]]},"reference":[{"issue":"22","key":"9961_CR1","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1001\/archinte.161.22.2733","volume":"161","author":"N Aslam","year":"2001","unstructured":"Aslam N, Marino C. Malignant ascites: new concepts in pathophysiology, diagnosis, and management. Arch Intern Med. 2001;161(22):2733\u20137.","journal-title":"Arch Intern Med"},{"issue":"6","key":"9961_CR2","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jamcollsurg.2004.01.035","volume":"198","author":"RA Adam","year":"2004","unstructured":"Adam RA, Adam YG. Malignant ascites: past, present, and future. J Am Coll Surg. 2004;198(6):999\u20131011.","journal-title":"J Am Coll Surg"},{"key":"9961_CR3","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/jco.2008.26.15_suppl.3000","volume":"28","author":"S Parsons","year":"2008","unstructured":"Parsons S, Murawa P, Koralewski P. Intraperitoneal treatment of malignant ascites due to epithelial tumours with catumaxomab. a phase II\/III study. J Clin Oncol. 2008;28:3000.","journal-title":"J Clin Oncol"},{"key":"9961_CR4","doi-asserted-by":"crossref","unstructured":"Heiss M, Murawa P, Koralewski P, Kolesnik O, Ivanchenko V, Dudnichenko A, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II\/III trial. Int J Cancer. 2010 (Epub ahead of print).","DOI":"10.1002\/ijc.25423"},{"issue":"8","key":"9961_CR5","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1182\/blood.V98.8.2526","volume":"98","author":"P Ruf","year":"2001","unstructured":"Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood. 2001;98(8):2526\u201334.","journal-title":"Blood"},{"issue":"2","key":"9961_CR6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1054\/bjoc.2000.1237","volume":"83","author":"R Zeidler","year":"2000","unstructured":"Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer. 2000;83(2):261\u20136.","journal-title":"Br J Cancer"},{"issue":"3","key":"9961_CR7","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.163.3.1246","volume":"163","author":"R Zeidler","year":"1999","unstructured":"Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol. 1999;163(3):1246\u201352.","journal-title":"J Immunol"},{"issue":"13","key":"9961_CR8","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/1078-0432.CCR-06-2769","volume":"13","author":"A Burges","year":"2007","unstructured":"Burges A, Wimberger P, K\u00fcmper C, Gorbounova V, Sommer H, Schmalfeldt B, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM \u00c3\u2014anti-CD3 antibody: a phase I\/II study. Clin Cancer Res. 2007;13(13):3899\u2013905.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"9961_CR9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ijc.21165","volume":"117","author":"M Heiss","year":"2005","unstructured":"Heiss M, Str\u00f6hlein M, J\u00e4ger M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer. 2005;117(3):435\u201343.","journal-title":"Int J Cancer"},{"issue":"3","key":"9961_CR10","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bjc.6603881","volume":"97","author":"P Ruf","year":"2007","unstructured":"Ruf P, Gires O, J\u00e4ger M, Fellinger K, Atz J, Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer. 2007;97(3):315\u201321.","journal-title":"Br J Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-9961-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-011-9961-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-011-9961-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T16:03:07Z","timestamp":1686067387000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-011-9961-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,5]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["9961"],"URL":"https:\/\/doi.org\/10.1007\/s12032-011-9961-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,5]]}}}